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Abstract
Background: Early myocardial reperfusion therapy (< 12 h) in patients with acute myocardial infarc-
tion (AMI) can significantly improve their prognosis. However, the effect of late reperfusion (> 12 h) 
remains controversial. In this study, the effects of late reperfusion versus standard drug therapy on the 
outcomes of patients with AMI were evaluated by systematic review and meta-analysis.
Methods: PubMed, Embase, Medline, Cochrane, Wanfang, and CNKI databases were searched for 
eligible studies for the present study. Meta-analysis was performed using RevMan 5.3.3 software. Rela-
tive risk (RR) and the 95% confidence interval (CI) were used to compare the outcomes between the two 
groups. The main outcome measures were major adverse cardiac events (MACEs), all-cause mortality, 
recurrent myocardial infarction (MI), and heart failure. 
Results: Eighteen studies were identified including 14,677 patients, of whom 5157 received late 
reperfusion with percutaneous coronary intervention (PCI) and 9520 received medication therapy 
(MT). Compared to MT, late PCI was associated with decreased all-cause mortality (RR 0.60, 95% CI 
0.44–0.83; p = 0.002), MACEs (RR 0.67; 95% CI 0.50–0.89; p < 0.001), and heart failure (RR 0.76; 
95% CI 0.60–0.97; p = 0.03), while there was also a trend toward decreased recurrent MI (RR 0.70; 
95% CI 0.47–1.05; p = 0.08). However, subgroup analysis according to time to PCI showed that the 
clinical benefit was only from PCI after 12 h but not from 2 to 60 days of the onset of symptoms.
Conclusions: The present meta-analysis suggested that PCI performed > 12 h but not 2–60 days after 
AMI is associated with significant improvement in clinical outcomes. However, these results need further 
rigorously designed large sample size clinical trials to be validated. (Cardiol J 2019; 26, 4: 333–342)
Key words: late reperfusion, percutaneous coronary intervention, clinical outcome, 
acute myocardial infarction, meta-analysis
Introduction
Acute myocardial infarction (AMI) is one of 
the leading causes of death worldwide [1]. Early 
myocardial reperfusion has become a primary 
therapeutic goal of ST-segment elevation myo-
cardial infarction (STEMI) [2]. A large number of 
clinical practices have confirmed that the opening 
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of an infarct related artery (IRA) within 12 h after 
onset significantly improved the prognosis of AMI 
patients [3–5]. However, there are two views on 
the treatment of patients over the reperfusion 
time window (> 12 h) in clinical practices. One is 
the standard drug treatment, including the double 
anti-platelet, b-blockers and statins, while another 
is the late reperfusion by percutaneous coronary 
intervention (PCI). However, the benefit of late 
PCI (> 12 h) has been controversial. Recent stud-
ies [6–8] have shown that late PCI may improve 
the cardiac function and clinical outcomes of AMI 
patients compared to medication therapy (MT). 
However, several studies reported conflicting 
results [9–11]. Abbate et al. [7] performed a meta-
analysis including 10 randomized controlled trials 
(RCTs) indicating that PCI of the IRA performed 
late (from 12 h to 60 days) after AMI is associated 
with significant improvements in cardiac function 
and survival. However, this published meta-analy-
sis included patients who received late PCI within 
12 h–60 days. That is, patients who received PCI 
with 12–48 h of the onset of symptoms were in-
cluded. In fact, the clinical outcomes may differ 
between individuals receiving PCI within 12–48 h 
and those receiving PCI within 2–60 days [9, 12]. 
Hochman et al. [9] reported that late PCI within 
3–28 days (median 8 days) after AMI did not show 
clinical benefit. However, Gierlotka et al. [12] 
found late reperfusion within 12–48 h reduced the 
12-month mortality rate compared to medication 
therapy alone in AMI patients. Therefore, although 
Abbate et al.’s [7] meta-analysis demonstrated that 
late PCI (from 12 h to 60 days) after AMI is associ-
ated with significant improvements in cardiac func-
tion and survival, the best cut-off of time window 
for late PCI remains uncertain. 
The aim of this study was to perform an up-
dated systematic review and meta-analysis of all 
eligible studies to further clarify the effect of late 
PCI versus MT on the prognosis of AMI patients 
and the best cut-off time window for late PCI.
Methods
Retrieval strategy
Eligible studies published in PubMed, Embase, 
Medline, Cochrane, Wanfang, and CNKI databases 
were searched from 1980 to November 2016 using 
the following keywords: “acute myocardial infarc-
tion (AMI)”; “percutaneous coronary intervention 
(PCI)”; “reperfusion”; “subacute myocardial infarc-
tion”; “acute coronary syndrome”; and “medication 
therapy”.
The main outcome measures were major ad-
verse cardiac events (MACEs), all-cause mortality, 
recurrent myocardial infarction, and heart failure 
(HF). Eligible studies published in both Chinese 
and English were included in the present study.
Inclusion and exclusion criteria
Randomized controlled trials were included, 
as well as observational studies and cohort studies 
in which: 1) enrolled patients with AMI received 
treatments of late reperfusion (> 12 h) or MT; 
2) compared outcomes between treatments of MT 
and later reperfusion; and 3) reported clinical out-
comes, such as all-cause mortality, MACEs, HF, 
and other outcomes.
Excluded were: 1) studies assessing the role 
of early reperfusion; 2) studies that only reported 
one therapy strategy; and 3) studies not involving 
human subjects.
Study selection
The procedure of eligible study selection is 
shown in Figure 1. Initially 1623 studies were 
searched. Of these, 1602 (98.7%) were excluded 
by title and abstract search because of irrelevant 
content, non-English and non-Chinese articles, 
animal subjects, outcomes of interest not reported, 
or other reasons. The remaining 21 studies were 
full-text reviewed, and 4 studies were excluded 
due to event rates not reported and outcomes of 
interest not reported. Finally, 18 studies [8–25] 
met the inclusion criteria and were included in the 
meta-analysis.
Data extraction
Two investigators (H.T.Y. and X.X.) carried 
out the data extraction using standardized data 
extraction forms. Discrepancies were resolved 
by consensus. The following information was col-
lected from each study: name of the first author, 
year of publication, ethnicity or geographic location 
of the study subjects, study design, procedural and 
management strategy, ages, gender, and relevant 
outcomes.
Outcomes
The primary outcomes for this systematic 
review were MACEs and all-cause mortality. Sec-
ondary outcomes were recurrent MI and HF.
Methodological quality
The recommendations of the Meta-analysis Of 
Observational Studies in Epidemiology (MOOSE) 
Group were followed to perform this meta-analysis, 
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including study selection, data collection, analysis, 
and reporting of the results.
Weighted risk ratios (RRs) were calculated 
and 95% confidence intervals (CIs) for categori-
cal variables and mean difference, and 95% CI for 
continuous variables. Heterogeneity testing was 
performed using the Cochrane Q-statistic and 
I2-statistic. Pooled effect sizes were determined using 
a fixed-effects model (the Mantel-Haenszel method) 
when heterogeneity was negligible (I2 < 50%) or 
a random-effects model (the DerSimonian and Kacker 
method) when significant heterogeneity was present 
(I2 ≥ 50%). Sensitivity analysis was also performed 
to evaluate the effect of each study on the combined 
RRs by omitting each study in turn. Publication bias 
was visually estimated by assessing funnel plots. All 
analyses were performed using RevMan 5.3.3 soft-
ware (Cochrane Collaboration, The Nordic Cochrane 
Centre, Copenhagen) as described previously.
Results
Study and patient characteristics
Table 1 listed the characteristics of the 
18 studies [8–25] that met eligibility criteria. Of 
these, 4 are observational studies [12. 14, 22, 23] and 
14 are RCTs [8–11, 13, 15–21, 24, 25]. The present 
analysis includes 14,677 patients, of whom 5157 
received late myocardial reperfusion and 9520 re-
ceived MT. The mean age of study participants was 
58.4 years.  Mean follow-up time was 12 months.
MACEs
Thirteen of 18 studies [8, 9, 11–18, 21, 23, 24] 
reported 1067 MACEs during follow-up. There 
was significant heterogeneity among included 
studies (I2 = 81%, p < 0.001); therefore, the 
random-effects model were used to calculate the 
RR value. In all patients, the meta-analysis results 
suggested that late PCI was associated with a lower 
incidence of MACEs (RR 0.67; 95% CI 0.50–0.89; 
p < 0.001, Fig. 2A) than MT. When stratified 
analysis according to time to PCI was performed, 
the heterogeneity disappeared in the > 12 h arm 
(I2 = 0%) and weakened in the 2–60 days arm 
(I2 = 79%). Subgroup analysis showed that 
a decreased MACE rate was observed only in the 
> 12 h arm but not in the 2–60 days arm (Table 2).
All-cause mortality
Fourteen of 18 studies [8, 9, 11–17, 20, 21, 
23–25] reported an outcome of all-cause mortality. 
Figure 1. Flow chart of identification of eligible studies; MT — medication therapy.
Abstracts excluded (n = 261), including:
1) Study design: n = 124 (i.e. case 
 reports, letters to the editor, 
 review articles)
2) Outcomes of interest not 
 reported: n = 116
3) Absence late reperfusion, 
 vs. MT comparison: n = 21
Records identied through 
database searching (n = 1623)
Abstracts after nonhuman 
and non-English or non-Chinese 
studies excluded (n = 1251)
Potential relevant abstracts 
reviewed (n = 282)
Full text articles assessed 
for eligibility (n = 21)
Finally included in the 
manuscript (n = 18)
Non-human and/or non-English 
and non-Chinese and exclusion 
of duplicated literatures (n = 372)
Studies excluded 
by non-relevant title 
(n = 969)
Full text articles excluded (n = 3):
1) Event rates not reported: n = 2
2) Outcomes of interest not
 reported: n = 1
336 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 4
T
ab
le
 1
. S
um
m
ar
y 
o
f k
ey
 d
em
o
gr
ap
hi
c 
ch
ar
ac
te
ri
st
ic
s 
o
f s
tu
d
ie
s 
in
cl
ud
ed
 in
 th
e 
m
et
a-
an
al
ys
is
.
Fi
rs
t 
au
th
o
r
P
ub
lic
at
io
n 
 
ye
ar
R
eg
io
n
S
am
p
le
  
si
ze
, n
N
o
. o
f 
 
P
C
I/
M
T
S
tu
d
y 
 
d
es
ig
n
T
im
e 
to
  
ad
m
is
si
o
n
M
an
ag
em
en
t 
st
ra
te
gy
M
ea
n 
fo
llo
w
 
up
 t
im
e
A
ge
  
[y
ea
rs
]
M
al
e 
 
se
x,
 %
O
ut
co
m
es
Fr
ei
xa
 e
t a
l. 
20
12
C
an
ad
a
10
24
47
2/
55
2
R
C
T
3–
28
 d
P
C
I (
D
E
S
/B
M
S
), 
M
T
5.
1 
y
P
C
I (
D
E
S
):
  
56
.9
 ±
 1
1.
3 
P
C
I (
B
M
S
):
  
57
.4
 ±
 1
0.
6 
M
T
: 
58
.7
 ±
 1
0.
9
P
C
I (
D
E
S
):
  
74
.7
 
P
C
I (
B
M
S
):
  
77
.4
 
M
T
: 
79
.0
M
A
C
E
s,
  
re
va
sc
ul
ar
iz
at
io
n,
 
d
ea
th
, r
ec
ur
re
nt
 
M
I, 
H
F
W
u 
et
 a
l. 
20
12
C
hi
na
14
6
47
/4
4
O
S
5–
10
 d
P
C
I/M
T
1 
m
56
.2
 ±
 1
3.
6
68
.4
M
A
C
E
s,
 a
rr
hy
th
m
ia
, 
d
ea
th
, H
F
Z
ey
m
er
 e
t a
l.
20
03
C
an
ad
a
30
0
14
9/
15
1
R
C
T
8–
42
 d
P
C
I/M
T
56
 m
P
C
I:
 5
8.
2 
±
 9
.2
 
M
T
: 
57
.5
 ±
 9
.8
P
C
I:
 8
4%
 
M
T
: 
89
%
M
A
C
E
s,
 n
o
nf
at
al
  
re
in
fa
rc
tio
n,
  
re
va
sc
ul
ar
iz
at
io
n,
 
d
ea
th
H
o
ri
e 
et
 a
l.
19
98
Ja
p
an
84
44
/3
9
R
C
T
1–
21
 d
P
T
C
A
/M
T
60
 m
P
T
C
A
: 
61
.8
 ±
 1
1.
9 
M
T
: 
61
.6
 ±
 8
.8
P
T
C
A
: 
77
%
 
M
T
: 
74
%
M
A
C
E
s,
 d
ea
th
/L
V
E
F 
(6
 m
), 
H
F,
  
re
cu
rr
en
t M
I
H
o
ch
m
an
 e
t a
l.
20
06
U
S
A
21
66
10
82
/1
08
4
R
C
T
3–
28
 d
P
C
I/M
T
34
 m
P
C
I:
 5
8.
6 
±
 1
0.
8 
M
T
: 
58
.7
 ±
 1
1.
1
P
C
I:
 7
8%
 
M
T
: 
78
%
M
A
C
E
s,
 d
ea
th
, H
F,
 
re
cu
rr
en
t M
I
S
te
g 
et
 a
l.
20
04
Fr
an
ce
21
2
10
9/
10
3
R
C
T
2–
15
 d
P
T
C
A
/M
T
35
 m
P
T
C
A
: 
56
 (5
0–
66
) 
M
T
: 
58
 (5
0–
66
)
P
T
C
A
: 
82
.5
%
 
M
T
: 
87
.2
%
M
A
C
E
s,
 d
ea
th
, H
F,
 
re
va
sc
ul
ar
iz
at
io
n,
 
re
cu
rr
en
t M
I
E
rn
e 
et
 a
l.
20
07
S
w
itz
er
la
nd
20
1
96
/1
05
R
C
T
3–
58
 d
P
C
I/M
T
10
.2
 y
P
C
I:
 5
4.
4 
±
 9
.1
 
M
T
: 
56
.2
 ±
 8
.8
P
C
I:
 8
8.
5%
 
M
T
: 
86
.7
%
M
A
C
E
s,
 r
ec
ur
re
nt
 
M
I, 
d
ea
th
,  
re
va
sc
ul
ar
iz
at
io
n
D
ža
ví
k 
et
 a
l.
20
06
U
S
A
38
1
19
5/
18
6
R
C
T
3–
28
 d
P
C
I/M
T
12
 m
P
C
I:
 5
7.
3 
(3
4–
80
) 
M
T
: 
57
.8
 (3
3–
81
)
P
C
I:
 8
3.
1%
 
M
T
: 
82
.3
%
LV
E
F
S
ch
ö
m
ig
 e
t a
l.
20
05
G
er
m
an
36
5
18
2/
18
3
R
C
T
12
–4
8 
h
P
C
I/M
T
3 
m
P
C
I:
 6
5.
7 
 
(5
7.
7–
73
.6
) 
M
T
: 
67
.1
  
(5
51
–7
3.
7)
P
C
I:
  
74
.2
 
M
T
: 
 
74
.4
LV
 in
fa
rc
t s
iz
e,
 
M
A
C
E
s
S
ilv
a 
et
 a
l.
20
05
C
an
ad
a
36
18
/1
2
R
C
T
12
 h
–1
4 
d
P
C
I/M
T
6 
m
P
C
I:
 5
6.
50
 ±
 9
.1
1 
M
T
: 
52
.8
3 
±
 9
.5
0
P
C
I:
 7
7.
78
 
M
T
: 
75
LV
E
F 
LV
 v
o
lu
m
e
D
za
vi
k 
et
 a
l.
19
94
C
an
ad
a
44
25
/1
9
R
C
T
5–
42
 d
P
T
C
A
/M
T
4 
m
P
T
C
A
: 
58
 ±
 1
2 
M
T
: 
59
 ±
 1
2
P
T
C
A
: 
72
%
 
M
T
: 
68
%
D
ea
th
Y
o
us
ef
 e
t a
l.
20
02
E
ng
la
nd
66
32
/3
4
R
C
T
3 
d
–4
 w
P
C
I/M
T
12
 m
P
C
I:
 5
9.
1 
±
 9
.7
 
M
T
: 
57
.6
 ±
 1
1.
2
P
C
I:
 8
1%
 
M
T
: 
80
%
M
A
C
E
s,
 d
ea
th
,  
re
cu
rr
en
t M
I, 
H
F,
 
re
va
sc
ul
ar
iz
at
io
n,
 
st
ro
ke
E
lli
s 
et
 a
l.
19
92
U
S
A
87
42
/4
5
R
C
T
>
 4
 d
P
T
C
A
/M
T
12
 m
P
T
C
A
: 
58
 ±
 9
 
M
T
: 
56
 ±
 1
0
P
T
C
A
: 
86
 
M
T
: 
82
M
A
C
E
s,
 d
ea
th
,  
re
cu
rr
en
t M
I, 
LV
E
F ≠
www.cardiologyjournal.org 337
Hai-Tao Yang et al., Late PCI and outcomes of AMI
There was significant heterogeneity among studies 
included (I2 = 55%, p = 0.009). The random-effects 
model was used to calculate the RR value. In total 
patients, relative to MT, late PCI was associated 
with decreased all-cause mortality (RR 0.62, 95% 
CI 0.43–0.92; p = 0.02, Fig. 2B). When stratified 
analysis according to time to PCI was performed, 
the heterogeneity disappeared in both the > 12 h 
arm (I2 = 0%) and the 2–60 days arm (I2 = 20%). 
Subgroup analysis showed that decreased mortality 
was observed only in the > 12 h arm but not in the 
2–60 days arm (Table 2).
Recurrent MI
There are 12 studies [8, 9, 11–17, 21, 23, 25] 
that reported the outcome of recurrent MI. Sig-
nificant heterogeneity existed among the included 
studies (I2 = 67%, p = 0.008). The random-effects 
model was used to calculate the RR value. In all pa-
tients, there was a trend toward decreased recurrent 
MI (RR 0.70; 95% CI 0.47–1.05; p = 0.08, Fig. 2C) 
in the late reperfusion group. When stratified 
analysis, according to time to PCI was performed, 
the heterogeneity disappeared in the > 12 h arm 
(I2 = 0%) but remained in the 2–60 days arm 
(I2 = 70%). Subgroup analysis showed late rep-
erfusion with > 12 h was significantly associated 
with deceased recurrent MI (RR 0.53; 95% CI 
0.39–0.72, p < 0.001). However, no difference was 
found between late reperfusion with 2–60 days and 
MT in recurrent MI (RR 0.84, 95% CI 0.46–1.51, 
p = 0.55, Table 2).
Heart failure
There are 8 studies [8, 9, 11, 13, 14, 16, 23, 24] 
that reported the outcome of HF. No significant 
heterogeneity existed among the studies included 
(I2 = 40%, p = 0.11). The fixed-effects model was 
used to calculate the RR value. The meta-analysis 
results showed that late reperfusion was associated 
with decreased incidence of HF rate (RR 0.76; 95% 
CI 0.60–0.97; p = 0.03, Fig. 2D). Similarly, sub-
group analysis showed late reperfusion PCI with 
> 12 h was significantly associated with decreased 
incidence of HF rate (RR 0.33; 95% CI 0.15–0.70; 
p = 0.004). However, a difference was not found 
between late reperfusion with 2–60 days and MT in 
HF (RR 0.85, 95% CI 0.66–1.10; p = 0.21, Table 2).
Sensitivity analysis
A sensitivity analysis was conducted to ex-
amine the influence of each study on the pooled 
RRs. The pooled RRs showed no significant change 
when one study was deleted individually. Further Ta
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Figure 2. Forest plots of association of late percutaneous coronary intervention (PCI) versus medication therapy (MT) 
with clinical outcomes. A. major adverse cardiac events; B. All-cause mortality; C. Recurrent myocardial infarction; 
D. Heart failure; CI — confidence interval.
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removed were the 4 observational studies in order 
to observe the stability of the results which also 
found no significant change in the pooled RRs, sug-
gesting the results are stable and credible.
Publication bias analysis
In the present study, funnel plots were utilized 
to evaluate the publication bias of all included 
studies. No publication biases were found for this 
meta-analysis (Fig. 3).
Discussion
The present meta-analysis is based on the 
statistical pooling of 18 studies that enrolled a total 
of 14,677 patients, comparing late reperfusion with 
conservative MT in patients presenting more than 
12 h after an AMI. Late PCI was reported (> 12 h) 
after AMI was associated with decreased MACEs, 
all-cause mortality, recurrent MI and HF. However, 
late PCI within 2–60 days after AMI is not associ-
ated with improvements in clinical outcomes. This 
is the first meta-analysis to not only clarify the 
effect of late PCI versus MT on the prognosis of 
AMI patients but also to answer just how late is 
too late for PCI after AMI. Nevertheless, there are 
several points to be discussed when interpreting 
the results.
Significant findings and clinical implications
The findings that > 12 h, but not 2–60 days 
of late reperfusion had a beneficial effect on the 
clinical outcomes of AMI patients are potentially 
very significant. In the real world, more than 
50% of patients undergo PCI during the subacute 
phase after an AMI [26–29]. Specifically, the cur-
rent ACC/AHA guidelines for PCI suggests that 
Figure 3. Funnel plot of test of publication bias; OR — 
odds ratio; SE — standard error.
Table 2. Subgroup analysis according to time to percutaneous coronary intervention.
Clinical outcomes I2 RR (95% CI) P 
All-cause mortality:
Total 57% 0.60 (0.44–0.83) 0.002
> 12 h 0% 0.47 (0.39–0.58) < 0.001
2–60 days 20% 0.82 (0.58–1.14) 0.24
Major adverse cardiac events:
Total 81% 0.67 (0.50–0.89) < 0.001
> 12 h 30% 0.46 (0.36–0.60) < 0.001
2–60 days 79% 0.77 (0.57–1.04) 0.09
Recurrent myocardial infarction:
Total 66% 0.70 (0.47–1.05) 0.08
> 12 h 0% 0.53 (0.39–0.72) < 0.001
2–60 days 70% 0.84 (0.46–1.51) 0.55
Heart failure:
Total 40% 0.76 (0.60–97) 0.03
> 12 h 61% 0.33 (0.15–0.70) 0.004
2–60 days 0% 0.85 (0.66–1.10) 0.21
CI — confidence interval; RR — relative risk
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late PCI is a class IIb (occluded artery) or class 
III (stenosis without evidence of spontaneous or 
provocable angina) indication [30]. However, the 
time point that is rational for PCI in the subacute 
phase of MI remains unclear. The present meta-
analysis clarified this issue and suggested that 
late PCI should not be performed later than 
2 days after the onset of symptoms. 
Pathophysiological mechanisms
The pathophysiological mechanisms of late 
PCI are propitious to the prognosis of AMI and 
may be explained as follows: Firstly, opening of an 
IRA is beneficial to the salvaging of “hibernating” 
myocardium from death, even if late and beyond 
the time limit set for salvaging from myocardial ne-
crosis [31]. Second, late reperfusion may favorably 
affect the apoptotic cascade, subsequently result-
ing in heart function protection [32]. In addition, 
opening of an IRA may interrupt the progression 
from hibernating myocardium to necrotic/apoptotic 
myocardium [33]. Busk et al. [34] observed the 
infarct size and myocardial salvage after primary 
angioplasty in patients presenting with symptoms 
for < 12 h vs. 12–72 h and supported that reduc-
ing time to treatment is pivotal because ‘time 
is muscle’. However, Busk et al. [34] also dem-
onstrated that substantial salvage was observed 
despite pain-to-balloon intervals of 12–72 h, even 
in patients with total occlusion of the IRA. Busk 
et al.’s [34] findings challenge the 12 h limit in 
primary angioplasty and suggest angioplasty of 
occluded IRAs should be performed within 48–72 h 
after AMI. Schömig et al. [18] also reported that 
primary angioplasty within 12–48 h reduced final 
infarct size and increased the salvage index when 
compared with MT. In the present data, clinical 
benefit was found from reperfusion with a > 12 h 
interval but not from a 2–60 day interval. The re-
sults are in line with the views of Busk et al. [34] 
and Schömig et al. [18]. 
Validity and potential limitations  
of the meta-analysis
This study has two advantages compared 
with Abbate et al.’s [8] meta-analysis published 
in 2008. The present study enrolled clinical trials 
that included a total of 14,677 AMI patients. Thus, 
results may be credible and stable. Identified pa-
tients received late PCI of > 12 h or 2–60 days, 
respectively and a concrete conclusion was made. 
Several potential limitations are worth men-
tioning. First, in meta-analysis, many of the studies 
included had different entry criteria, study popula-
tions, clinical outcomes, time to PCI, and follow-up 
time. This is a source of increased heterogeneity 
that may limit the generalizability of the conclu-
sions to a broader AMI population. Therefore, 
a subgroup analysis was made and found heteroge-
neity disappeared or decreased. Second, there are 
4 studies designed not as randomized trials, and 
therefore different study designs may influence 
results. Third, the participants in some studies 
including both PCI of within 12–48 h and within 
2–60 days could not be divided into two groups 
to perform meta-analysis because of absence of 
stratification in the original studies. Thus, there 
is a proportion of 2–60 days PCI patients mixed 
in the > 12 h PCI subjects. Therefore, the results 
need to be verified by further rigorously designed 
large sample size clinical trials.
Conclusions
This meta-analysis of data from 18 studies 
shows beneficial outcomes in performing PCI late 
(> 12 h) in the course of an AMI. However, PCI 
performed later than 2 days after onset of AMI may 
be unnecessary in clinical practice.
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